PT Hetzer Medical Indonesia Tbk (IDX:MEDS)
Indonesia · Delayed Price · Currency is IDR 74.00
-1.00 (-1.33%)
Sep 2, 2026, 2:17 PM WIB
IDX:MEDS Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,011 | 6,629 | 6,391 | 22,723 | 37,737 | 75,790 | |
Revenue Growth | 265.88% | 3.72% | -71.88% | -39.79% | -50.21% | -13.67% |
Cost of Revenue | 10,280 | 6,261 | 5,866 | 12,086 | 16,712 | 21,812 |
Gross Profit | 4,731 | 368.02 | 525.3 | 10,637 | 21,025 | 53,978 |
Selling, General & Admin | 8,755 | 8,638 | 9,199 | 13,240 | 16,472 | 19,914 |
Operating Expenses | 8,755 | 8,638 | 9,199 | 13,240 | 16,472 | 19,914 |
Operating Income | -4,024 | -8,270 | -8,674 | -2,603 | 4,553 | 34,064 |
Interest Expense | -726.06 | -672.71 | -482.4 | -663.42 | -759.2 | -180.42 |
Interest & Investment Income | 253.78 | 253.5 | 0.82 | 2.85 | 24.42 | 233.16 |
Other Non Operating Income (Expenses) | 118.67 | 121.75 | 881.55 | -323.87 | -3,222 | 10.95 |
Pretax Income | -4,377 | -8,568 | -8,274 | -3,587 | 596.32 | 34,128 |
Income Tax Expense | -221.9 | -221.9 | 259.95 | -17.01 | 359.25 | 7,496 |
Net Income | -4,156 | -8,346 | -8,534 | -3,570 | 237.06 | 26,631 |
Net Income to Common | -4,156 | -8,346 | -8,534 | -3,570 | 237.06 | 26,631 |
Net Income Growth | - | - | - | - | -99.11% | -29.85% |
Shares Outstanding (Basic) | 1,563 | 1,563 | 1,563 | 1,563 | 1,373 | 1,250 |
Shares Outstanding (Diluted) | 1,563 | 1,563 | 1,563 | 1,563 | 1,373 | 1,250 |
Shares Change | - | - | - | 13.78% | 9.86% | - |
EPS (Basic) | -2.66 | -5.34 | -5.46 | -2.29 | 0.17 | 21.31 |
EPS (Diluted) | -2.66 | -5.34 | -5.46 | -2.29 | 0.17 | 21.31 |
EPS Growth | - | - | - | - | -99.19% | -29.85% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3,725 | -2,731 | 1,954 | -2,932 | -30,995 | -13,524 |
Free Cash Flow Per Share | -2.38 | -1.75 | 1.25 | -1.88 | -22.57 | -10.82 |
Gross Margin | 31.52% | 5.55% | 8.22% | 46.81% | 55.71% | 71.22% |
Operating Margin | -26.81% | -124.76% | -135.72% | -11.46% | 12.07% | 44.95% |
Profit Margin | -27.68% | -125.90% | -133.52% | -15.71% | 0.63% | 35.14% |
Free Cash Flow Margin | -24.82% | -41.20% | 30.58% | -12.90% | -82.13% | -17.84% |
EBITDA | -128.86 | -4,321 | -4,472 | 985.21 | 7,254 | 35,591 |
EBITDA Margin | -0.86% | -65.18% | -69.97% | 4.34% | 19.22% | 46.96% |
D&A For EBITDA | 3,895 | 3,950 | 4,202 | 3,588 | 2,701 | 1,527 |
EBIT | -4,024 | -8,270 | -8,674 | -2,603 | 4,553 | 34,064 |
EBIT Margin | -26.81% | -124.76% | -135.72% | -11.46% | 12.07% | 44.95% |
Effective Tax Rate | - | - | - | - | 60.25% | 21.96% |